--- title: "Aprea Therapeutics (APRE) news: offering" url: "https://aibio.space/companies/aprea-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "APRE offering news: Aprea reports first-quarter 2026 results and $46.5 million in cash. Aprea Therapeutics, Inc. (NASDAQ: APRE), United States." --- APRE Aprea Therapeutics, Inc. NASDAQ · United States # Aprea Therapeutics (APRE) news APRE offering news Company Updates · 2026-08-28 ## [Aprea Therapeutics reports expanded patent portfolio for WEE1 and ATR programs](https://aibio.space/news/aprea-therapeutics-reports-expanded-patent-portfolio-wee1-atr-programs/) Aprea said it holds 28 issued and 30 pending patents for its precision oncology programs, with the WEE1 family of applications expiring in 2047 if granted. ## Latest Aprea Therapeutics news 1. 2026-08-12 Company Updates [Aprea reports second-quarter 2026 results and $41.2 million in cash](https://aibio.space/news/aprea-reports-second-quarter-2026-results-41-2-million-cash/) Aprea Therapeutics reported a net loss of $3.6 million for the quarter ended June 30, 2026, and said its cash should last into the first quarter of 2028. The company is also expanding enrollment in its lead WEE1 inhibitor trial. 2. 2026-05-13 Company Updates [Aprea reports first-quarter 2026 results and $46.5 million in cash](https://aibio.space/news/aprea-reports-first-quarter-2026-results-46-5-million-cash/) Aprea said its $30 million private placement closed on March 31, 2026, and reported $46.5 million in cash at March 31, 2026, with runway into the first quarter of 2028. The company also described two partial responses in its Phase 1 trial of APR-1051. 3. 2026-01-29 Financings [Aprea Therapeutics agrees to $5.6 million private placement priced at-the-market under Nasdaq rules](https://aibio.space/news/aprea-therapeutics-agrees-5-6-million-private-placement-priced-market/) Aprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026. ## Aprea Therapeutics at a glance - **Ticker**: APRE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $41.2 million ### Related companies - [Silo Pharma](https://aibio.space/companies/silo-pharma/) NASDAQ: SILO - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) NASDAQ: PTGX - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) NASDAQ: GYRE - [Alzamend Neuro](https://aibio.space/companies/alzamend-neuro/) NASDAQ: ALZN - [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) NASDAQ: RIGL - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [Ernexa Therapeutics](https://aibio.space/companies/ernexa-therapeutics/) NASDAQ: ERNA ### Also on NASDAQ - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) RNAC - [Pasithea Therapeutics](https://aibio.space/companies/pasithea-therapeutics/) KTTA - [NOMAD POWER SOLUTIONS, INC.](https://aibio.space/companies/nomad-power-solutions/) NMAD - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) OBX - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) IMMX - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) CAPR ## What Aprea Therapeutics does Aprea Therapeutics, Inc. describes itself as a clinical-stage precision medicine oncology company that develops small molecule inhibitors designed to exploit genetic mutations in cancer, using an approach called synthetic lethality. Its lead WEE1 inhibitor, APR-1051, is in a Phase 1 dose-escalation study, ACESOT-1051, which plans 9 cohorts evaluating doses of 10 mg to 300 mg once daily. The company announced unconfirmed partial responses in patients with PPP2R1A-mutated endometrial cancer. Its second clinical-stage program, ATRN-119, is an oral macrocyclic ATR inhibitor. The company determined a recommended Phase 2 dose of 1,100 mg once daily in a Phase 1/2a study, then paused enrollment in the monotherapy arms while it explores combinations, including with radiation in head and neck cancer. APR-1602, a DYRK1A/B inhibitor, is preclinical. The company acquired Atrin Pharmaceuticals Inc. in May 2022, and it has no ongoing clinical trials of its mutant p53 reactivator, APR-246. | Product or program | What it is | Stage | |---|---|---| | APR-1051 | WEE1 inhibitor for biomarker-defined cancers | Phase 1 dose escalation | | ATRN-119 (mosipasertib) | Oral macrocyclic ATR inhibitor for advanced solid tumors | Phase 1/2a; monotherapy enrollment paused | | APR-1602 | Macrocyclic DYRK1A/B inhibitor | Preclinical | | APR-246 (eprenetapopt) | Reactivator of mutant p53 | No ongoing clinical trials | Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/apre-20251231x10k.htm). ## Aprea Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$12.6 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/) | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/) | | Cash from operations | [-$12.9 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/) | [-$13.6 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/) | | Cash and equivalents | [$14.6 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926094544/) | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028068/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $41.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Aprea Therapeutics Has Aprea Therapeutics raised money recently? Our latest story on this, dated May 13, 2026: "Aprea reports first-quarter 2026 results and $46.5 million in cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aprea-reports-first-quarter-2026-results-46-5-million-cash/). What is the ticker symbol of Aprea Therapeutics? Aprea Therapeutics, Inc. trades under the ticker APRE on NASDAQ. Where is Aprea Therapeutics listed? Aprea Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Aprea Therapeutics? The SEC Central Index Key (CIK) for Aprea Therapeutics, Inc. is 1781983. Its filings are on SEC EDGAR. How many shares does Aprea Therapeutics have outstanding? 12,591,136 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Aprea Therapeutics listed under? Our directory records Aprea Therapeutics, Inc. under United States. What does Aprea Therapeutics do? Our directory classifies Aprea Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Aprea Therapeutics? The ISIN recorded for Aprea Therapeutics, Inc. is US03836J2015. Does aibio.space cover Aprea Therapeutics? aibio.space lists Aprea Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Aprea Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Aprea Therapeutics develop? Aprea Therapeutics, Inc. describes itself as a clinical-stage precision medicine oncology company that develops small molecule inhibitors designed to exploit genetic mutations in cancer, using an approach called synthetic lethality. Its lead WEE1 inhibitor, APR-1051, is in a Phase 1 dose-escalation study, ACESOT-1051, which plans 9 cohorts evaluating doses of 10 mg to 300 mg once daily. What is APR-1051 from Aprea Therapeutics? APR-1051: WEE1 inhibitor for biomarker-defined cancers Stage: Phase 1 dose escalation. What is ATRN-119 (mosipasertib) from Aprea Therapeutics? ATRN-119 (mosipasertib): Oral macrocyclic ATR inhibitor for advanced solid tumors Stage: Phase 1/2a; monotherapy enrollment paused. Is Aprea Therapeutics profitable? Aprea Therapeutics, Inc. reported a net loss of $12.6 million for the fiscal year ended Dec 31, 2025, and used $12.9 million of cash in operations, per its annual report to the SEC. How much cash does Aprea Therapeutics have? $41.2 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Aprea Therapeutics Members talk about Aprea Therapeutics (APRE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Aprea Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm) 2. 2026-06-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/tm2618205d1_8k.htm) 3. 2026-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926052044/apre-20260616xdef14a.htm) 4. 2026-04-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926045158/apre-20260616xpre14a.htm) 5. 2026-03-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926036821/tm2610566d1_ex99-1.htm) 6. 2026-01-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_ex99-1.htm) 7. 2026-01-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1781983/000110465926006267/tm263963d1_8k.htm) 8. 2025-03-25 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1781983/000155837025003588/apre-20241231x10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:APRE on TradingView](https://www.tradingview.com/symbols/NASDAQ-APRE/). ## SEC filings and registration - **SEC name**: Aprea Therapeutics, Inc. - **CIK**: 1781983 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: APRE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902 - **Phone**: 215-948-4119 - **Shares outstanding**: 12,591,136 as of 2026-08-12 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1781983/000110465926102795/apre-20260828x8k.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1781983/000110465926094544/apre-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1781983/000110465926094542/apre-20260812x8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/tm2618205d1_8k.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1781983/000110465926059743/apre-20260331x10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513x8k.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1781983/000110465926052044/apre-20260616xdef14a.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001781983), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Aprea Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker APRE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Aprea Therapeutics, Inc. - **Ticker**: APRE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03836J2015 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-APRE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/aprea-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aprea Therapeutics (APRE) news: offering", 2026-10-31, https://aibio.space/companies/aprea-therapeutics/